Fate Therapeutics Statistics
NASDAQ: FATEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
2.15-0.14 (-6.11%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Fate Therapeutics by the numbers
Fate Therapeutics has a market capitalization of $257.6 million based on 119.82M shares outstanding. With trailing EPS of $-1.05, Fate Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 13.1% below its 50-day average and 15.3% above its 200-day average.
Average daily trading volume is 1.90M shares, or about $4.1 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
FATE valuation vs. peer median
| Metric | FATE | Peer median | Difference |
|---|---|---|---|
| Market cap | $257.61M | $266.37M | -3% |
| Avg. volume | 1.90M | 754.96K | +152% |
Peer median across 8 companies: LXEO, IKT, XFOR, SABS, PALI, SRZN, STRO, LCTX.
Valuation
- Market cap
- $257.61M
- EPS (TTM)
- $-1.05
- Shares outstanding
- 119.82M
Price and trading
- Previous close
- 2.29
- Open
- 2.28
- Day range
- 2.14 – 2.30
- 52-week range
- 0.95 – 3.23
- 52-week change
- +54.68%
- Beta
- —
- Volume
- 861.15K
- Average volume
- 1.90M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Aug 13, 2026
Additional statistics
- Market Cap
- 257.61M
- Forward Pe
- -2.22
- Eps
- -1.05
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 3.23
- Week52 Low
- 0.95
- Avg Volume
- 1.90M
- Shares Outstanding
- 119.82M
- Ma50
- 2.47
- Ma200
- 1.86
- Earnings Date
- Aug 13, 2026
- Pct From52w High
- -33.44%
- Pct From52w Low
- 126.32%